Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Year
  • 1
    Language: English
    In: PLoS ONE, 01 January 2016, Vol.11(3), p.e0150632
    Description: Patients with acute myeloid leukemia (AML) who undergo induction chemotherapy are at high risk for invasive fungal disease (IFD). Dectin-1, a C-type lectin family member represents one of the most important pattern recognition receptors of the...
    Keywords: Sciences (General)
    E-ISSN: 1932-6203
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: Annals of Hematology, 2015, Vol.94(12), pp.2063-2065
    ISSN: 0939-5555
    E-ISSN: 1432-0584
    Source: Springer Science & Business Media B.V.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Journal of Cancer Research and Clinical Oncology, 2015, Vol.141(9), pp.1661-1668
    Description: Byline: Karin G. Schrenk (1), Ulf Schnetzke (1), Katy Stegemann (1), Marie Lilienfeld-Toal (1), Andreas Hochhaus (1), Sebastian Scholl (1) Keywords: Posaconazole; IFD; AML; Induction chemotherapy Abstract: Background Severe infectious complications reflect a continuing problem in patients with acute myeloid leukemia (AML). Based on data from a randomized clinical trial demonstrating a reduction of proven and probable invasive fungal disease (IFD), posaconazole has been approved for prophylaxis of fungal infections in AML patients during induction chemotherapy. Nevertheless, recently published observational studies show contradictory results concerning the efficacy of posaconazole in this clinical setting. Furthermore, oral suspension posaconazole is associated with an unpredictable bioavailability that especially depends on nutritional factors or gastric pH value. Patients and methods We retrospectively analyzed the impact of posaconazole prophylaxis in 70 consecutively evaluable AML patients who underwent induction chemotherapy at a tertiary care hospital. The incidence of IFD classified as proven, probable or possible, antifungal therapy including empiric treatment in high-risk patients and tolerability of posaconazole were determined. In addition, important clinical cofactors such as co-treatment with proton pump inhibitors and risk factors for pneumonia were analyzed in this study. Results We can demonstrate that posaconazole is well tolerated and had to be stopped in only six patients (8.6 %). The overall incidence of IFD was 30 % including two patients with proven (2.8 %), four patients with probable (5.7 %) and 15 patients with possible IFD (21.4 %). Importantly, 24 out of 49 patients (49.0 %) who did not fulfill the criteria of IFD received empiric antifungal therapy. Including patients classified as possible IFD, 39 of 70 patients (55.7 %) underwent at least first-line antifungal treatment. Conclusion Our "real-life" data obtained from 70 AML patients after induction chemotherapy demonstrate the frequent necessity of systemic antifungal treatment despite prophylaxis with oral suspension posaconazole. Author Affiliation: (1) Klinik fur Innere Medizin II (Abteilung Hamatologie und Internistische Onkologie), Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany Article History: Registration Date: 17/03/2015 Received Date: 13/02/2015 Accepted Date: 16/03/2015 Online Date: 24/03/2015
    Keywords: Posaconazole ; IFD ; AML ; Induction chemotherapy
    ISSN: 0171-5216
    E-ISSN: 1432-1335
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Journal of cancer research and clinical oncology, May 2016, Vol.142(5), pp.1133-6
    Description: To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00432-015-2084-1 Byline: Max Desole (1), Karin G. Schrenk (1), Ulf Schnetzke (1), Andreas Hochhaus (1), Sebastian Scholl (1) Author Affiliation: (1) Klinik fur Innere Medizin II (Abteilung Hamatologie und Internistische Onkologie), Universitatsklinikum Jena, Erlanger Allee 101, 07740, Jena, Germany Article History: Registration Date: 18/11/2015 Received Date: 15/11/2015 Accepted Date: 18/11/2015 Online Date: 30/11/2015
    Keywords: Bacterial Infections -- Diagnosis ; Bronchoalveolar Lavage Fluid -- Microbiology ; Enterococcus -- Isolation & Purification ; Hematologic Diseases -- Complications ; Neutropenia -- Diagnosis
    ISSN: 01715216
    E-ISSN: 1432-1335
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Annals of Hematology, 2013, Vol.92(7), pp.985-987
    Description: Byline: Karin G. Schrenk (1), Manuela Krokowski (2), Alfred C. Feller (2), Veronica Bernhard (2), Lars-Olof Mugge (1), Peter Oelzner (3), Gunter Wolf (3), Andreas Hochhaus (1), Thomas Neumann (3) Author Affiliation: (1) Abteilung fur Hamatologie und internistische Onkologie, Klinik fur Innere Medizin II, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany (2) Institut fur Pathologie, Referenzzentrum fur Lymphknotenpathologie und Hamatopathologie, Universitat Lubeck, Ratzeburger Allee 160, 23538, Lubeck, Germany (3) Abteilung fur Nephrologie, Rheumatologie/Osteologie, Endokrinologie/Stoffwechselerkrankungen Klinik fur Innere Medizin III, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany Article History: Registration Date: 03/12/2012 Received Date: 13/07/2012 Accepted Date: 01/12/2012 Online Date: 16/01/2013
    Keywords: Leukemia;
    ISSN: 0939-5555
    E-ISSN: 1432-0584
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Annals of Hematology, 2014, Vol.93(12), pp.2077-2079
    Description: Byline: Ulf Schnetzke (1), Karin Schrenk (1), Barbel Spies-Weisshart (1), Christa Kunert (1), Andreas Hochhaus (1), Sebastian Scholl (1) Author Affiliation: (1) Klinik fur Innere Medizin II (Abteilung Hamatologie und Internistische Onkologie), Universitatsklinikum Jena, Erlanger Allee 101, 07740, Jena, Germany Article History: Registration Date: 21/04/2014 Received Date: 08/04/2014 Accepted Date: 21/04/2014 Online Date: 07/05/2014
    Keywords: Cancer Treatment;
    ISSN: 0939-5555
    E-ISSN: 1432-0584
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Annals of hematology, December 2015, Vol.94(12), pp.2063-5
    Description: Byline: Karin G. Schrenk (1), Kathrin Katenkamp (2), Jorg Felber (3), Lars-Olof Mugge (1), Andreas Hochhaus (1), Sebastian Scholl (1,4) Author Affiliation: (1) Klinik fur Innere Medizin II (Abteilung Hamatologie und Internistische Onkologie), Universitatsklinikum Jena, Jena, Germany (2) Institut fur Pathologie, Universitatsklinikum Jena, Jena, Germany (3) Klinik fur Innere Medizin IV (Gastroenterologie, Hepatologie und Infektiologie), Universitatsklinikum Jena, Jena, Germany (4) Department of Internal Medicine II, Erlanger Allee 101, 07740, Jena, Germany Article History: Registration Date: 31/07/2015 Received Date: 11/05/2015 Accepted Date: 29/07/2015 Online Date: 21/08/2015
    Keywords: Antineoplastic Agents -- Adverse Effects ; Bortezomib -- Adverse Effects ; Crohn Disease -- Therapy ; Gastrointestinal Hemorrhage -- Etiology ; Leukemia, Plasma Cell -- Therapy ; Stem Cell Transplantation -- Adverse Effects
    ISSN: 09395555
    E-ISSN: 1432-0584
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: Journal of Cancer Research and Clinical Oncology, 2016, Vol.142(5), pp.1133-1136
    ISSN: 0171-5216
    E-ISSN: 1432-1335
    Source: Springer Science & Business Media B.V.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Journal of Cancer Research and Clinical Oncology, 2014, Vol.140(8), pp.1391-1397
    Description: Byline: Ulf Schnetzke (1), Peter Fix (3), Baerbel Spies-Weisshart (1), Karin Schrenk (1), Anita Glaser (2), Hans-Joerg Fricke (1), Paul Rosee (1), Andreas Hochhaus (1), Sebastian Scholl (1) Keywords: AML; Relapse; FLT3; Cyclophosphamide; Stem cell transplantation Abstract: Background Approximately, 70 % of adult patients with de novo acute myeloid leukemia (AML) achieve a complete remission (CR) while 10--20 % of AML are refractory to induction chemotherapy. Furthermore, a significant proportion of AML patients in CR will relapse during or after consolidation treatment. There is no evidence for a standard salvage regimen and most centers use a combination of an anthracycline and cytarabine (AraC). The aim of this study was to investigate the impact of two age-adjusted regimens containing AraC and cyclophosphamide applied for the treatment of relapsed or refractory AML. Patients and methods We retrospectively analyzed 60 patients (24 male, 36 female median age 56 years) with relapsed or refractory AML who were treated with a combination of AraC and cyclophosphamide monocentrically between October 2000 and January 2013. Two different protocols containing either high-dose (hAC) or intermediate-dose cytarabin (iAC) have been applied dependent on age and performance status. Results We demonstrate an overall response rate (CR + PR) induced by hAC and iAC of 56.7 %. Importantly, a complete remission rate (CR + CRp) of 52.2 % was found in patients who received the hAC regimen while only 8.8 % of patients achieved a CR following the iAC protocol (p 〈 0.001). The rate of refractory disease was 26.1 and 47.1 %, respectively. High-risk cytogenetics, i.e., a complex aberrant or monosomal karyotype had no effect on achievement of CR after hAC. In addition, there was no impact of activating FLT3 mutations on response to treatment according to the hAC regimen. In the cohort of patients treated with the iAC protocol, treatment-related mortality of 11.8 % within 60 days was observed but none of the patients who received the hAC regimen died within the first 2 months following chemotherapy. The toxicity profile was acceptable at both cytarabine dose levels. Importantly, 19 patients (82.6 %) of the hAC cohort underwent allogeneic hematopoietic stem cell transplantation (HSCT) as consecutive treatment. Conclusion The hAC regimen represents a promising therapeutic approach to induce a second CR in younger patients with relapsed or refractory AML prior to HSCT without using anthracyclines. Author Affiliation: (1) Abteilung Hamatologie und Internistische Onkologie, Klinik fur Innere Medizin II, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany (2) Institut fur Humangenetik, Universitatsklinikum Jena, Jena, Germany (3) Abteilung Internistische Onkologie und Hamatologie, Zentralklinik Bad Berka, Bad Berka, Germany Article History: Registration Date: 28/03/2014 Received Date: 12/03/2014 Accepted Date: 28/03/2014 Online Date: 12/04/2014 Article note: Ulf Schnetzke and Peter Fix have contributed equally to this work.
    Keywords: AML ; Relapse ; FLT3 ; Cyclophosphamide ; Stem cell transplantation
    ISSN: 0171-5216
    E-ISSN: 1432-1335
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: Annals of Hematology, Jan, 2016, Vol.95(2), p.355(3)
    Description: Byline: Karin G. Schrenk (1), Janina Frosinski (2), Sebastian Scholl (1), Sylvia Otto (3), Paul Rosee (1), Andreas Hochhaus (1), Mathias W. Pletz (2) Keywords: MRSA; Daptomycin; Akute myeloid leukemia; Cerebral embolism Author Affiliation: (1) Klinik fur Innere Medizin II, Hamatologie und Internistische Onkologie, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany (2) Zentrum fur Infektionsmedizin und Krankenhaushygiene, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany (3) Klinik fur Innere Medizin I, Kardiologie, Angiologie, Pneumologie und Internistische Intensivmedizin, Universitatsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany Article History: Registration Date: 06/10/2015 Received Date: 03/10/2015 Accepted Date: 06/10/2015 Online Date: 21/10/2015
    Keywords: Staphylococcus Aureus Infections -- Care And Treatment ; Stroke -- Care And Treatment ; Embolism -- Care And Treatment ; Leukemia -- Care And Treatment ; Staphylococcus Aureus
    ISSN: 0939-5555
    Source: Cengage Learning, Inc.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages